ABSTRACT
Phytosterol-esters were developed by Unilever as a cholesterol lowering novel food ingredient for use initially in vegetable oil spreads. In addition to an extensive package of safety studies and clinical studies a programme of post-launch monitoring (PLM) was developed. PLM was used to address the following questions: (a) Is the product use as predicted/recommended? (b) Are the known effects as predicted? (c) Does the product cause unexpected health effects? The overall conclusions from the PLM programme were: the product is being bought by the target population but intakes are less than the original assumptions made in the risk assessment; long-term use of phytosterol-ester enriched spreads results in a reduction in the serum levels of the most lipophilic carotenoids but at current levels of intake this is unlikely to result in reductions in carotenoids that are of biological significance; evaluation of health related consumer complaints have not indicated any unexpected health effects associated with the use of the product in the marketplace. As part of the European approval under Regulation (EC) No. 258/97 on Novel Foods and Food Ingredients the results of the PLM programme had to be submitted to the European Commission (EC) and reviewed by the Scientific Committee on Food (SCF). They concluded that the study provided valuable information, which complemented the pre-market safety evaluation studies, and that the EC mandatory requirement had been met.
Subject(s)
Phytosterols/administration & dosage , Phytosterols/adverse effects , Product Surveillance, Postmarketing , Carotenoids/blood , Double-Blind Method , Esters/administration & dosage , Esters/adverse effects , European Union , Female , Humans , Male , Margarine , Middle Aged , Plant OilsABSTRACT
Vegetable oil spreads containing phytosterol-esters are marketed as a cholesterol-lowering functional food in more than 20 countries worldwide. An extensive package of safety data has shown phytosterol-esters to be safe for human use. However, even though phytosterols are very stable molecules, oxidation may occur at low levels under extreme heating conditions, resulting in phytosterol oxides. As there is some suggestion of adverse biological effects in the literature for the related cholesterol oxidation products, safety data have been generated for phytosterol oxides. A phytosterol oxide concentrate (POC) was generated by prolonged heating of phytosterol-esters in the presence of oxygen. The genotoxicity and subchronic toxicity of this mixture was assessed in a series of in vitro genotoxicity assays (bacterial mutation, chromosome aberration and micronucleus) and a subchronic feeding study in the rat. Results showed that a phytosterol oxide concentrate containing approximately 30% phytosterol oxides did not possess genotoxic potential and no obvious evidence of toxicity when administered in the diet of the rat for 90 consecutive days. In the latter study, a NOEL was established at an estimated dietary level of phytosterol oxides of 128 mg/kg/day for males and 144 mg/kg/day for females. In conclusion, these materials have been shown to raise no obvious concerns for human safety.
Subject(s)
Chromosome Aberrations/chemically induced , Oxides/toxicity , Phytosterols/toxicity , Administration, Oral , Animals , Body Weight/drug effects , Consumer Product Safety , Dose-Response Relationship, Drug , Eating/drug effects , Esters , Female , Male , Micronucleus Tests , Mutagenicity Tests , No-Observed-Adverse-Effect Level , Oxidation-Reduction , Random Allocation , Rats , Rats, Wistar , Risk Assessment , Salmonella typhimurium/drug effects , Toxicity TestsABSTRACT
Post-market surveillance (PMS) is increasingly required by some regulatory authorities for the marketing approval of GM-Novel Foods. This requirement, in addition to a complete conventional safety assessment, aims to show that unexpected (adverse) effects do not occur after long-term everyday exposure. Large food manufacturers have systems to obtain feedback from consumers on their products. We show that such systems can be enhanced to collect information on possible health effects of specific products and relate these to intake in specific groups of consumers. The term post-launch monitoring (PLM) is proposed to distinguish the process from that used for pharmaceuticals. GM foods differ from branded products to which existing systems have been applied. The paper discusses whether and how such systems could be applied to GM foods and what additional elements would need to be incorporated in them. A PLM system should define and organize the flow of information between the different stakeholders. We conclude that because such data will be generated from a range of sources and will need to be collated, verified, and integrated, an independent agency will be essential to undertake this activity in order to balance the interests of all stakeholders and ensure public trust.
Subject(s)
Food, Genetically Modified/standards , Pharmaceutical Preparations/standards , Product Surveillance, Postmarketing/methods , Product Surveillance, Postmarketing/standards , Drug Industry/standards , Drug-Related Side Effects and Adverse Reactions , Food Industry/standards , Food, Genetically Modified/adverse effectsABSTRACT
For the prediction of skin sensitization potential of substances, the murine local lymph node assay (LLNA) is an alternative to the widely used guinea pig tests. For more than 10 years, this method has undergone extensive development, evaluation, and validation. In this review, the validation status of the LLNA is considered, specifically with regard to its use for regulatory identification of skin sensitization hazards. The LLNA is a method for the predictive identification of chemicals that have a potential to cause skin sensitization. Activity is measured as a function of lymph node cell proliferative responses stimulated by topical application of test chemicals. The LLNA has successfully passed all reasonable validation stages. It provides a reliable and relevant source of predictive skin sensitization data, which unlike results from guinea pig tests, are reproducible from laboratory to laboratory. In summary, the LLNA is now ready for acceptance as a viable and complete alternative to traditional methods, offering a substantial reduction in animal numbers and refinement opportunities without compromising the standards for the identification of important skin sensitizers.
Subject(s)
Allergens , Dermatitis, Allergic Contact/diagnosis , Lymph Nodes/pathology , Skin Tests/standards , Animals , Disease Models, Animal , Female , Guinea Pigs , Humans , Mice , Mice, Inbred CBA , Predictive Value of Tests , Reproducibility of ResultsABSTRACT
BACKGROUND: The murine local lymph node assay (LLNA) has been validated as an alternative method for the identification of skin sensitization hazards. Contact allergens are identified as a function of proliferative responses induced in draining lymph nodes. The quantitative nature of the LLNA data also provides the opportunity of assessing relative potency by reference to dose response analyses. OBJECTIVE: In the current investigations, the influence of vehicle on the skin sensitization potency of a known skin sensitizer (1,4-dihydroquinone) was assessed. METHODS: 1, 4-dihydroquinone was tested in the LLNA using 7 different vehicle systems in each of 2 independent laboratories. RESULTS: Results from the 2 laboratories were almost identical. LLNA dose response data were interpolated to derive the estimated concentration (EC) of 1, 4-dihydroquinone necessary to cause a three-fold stimulation of proliferation compared with controls, the EC3 value. The vehicles used and mean EC3 values obtained were: methyl ethyl ketone 0.07%, acetone 0.08%, acetone/olive oil (80/20 v/v) 0.15%, dimethyl formamide 0.22%, dimethyl sulfoxide 0.4%, and propylene glycol and acetone/saline (50/50 v/v) vehicles gave negative results. However, when tested at higher concentrations, positive results were obtained in these vehicles. CONCLUSION: These data reveal that the vehicle in which a chemical is encountered in the skin can have a significant impact on a quantitative measure of skin sensitization potency. The implication is that accurate assessment of risk to humans will require an understanding of the matrix in which skin exposure is likely to occur.
Subject(s)
Dermatitis, Allergic Contact/diagnosis , Dermatitis, Allergic Contact/immunology , Immunization/methods , Lymph Nodes/immunology , Pharmaceutical Vehicles/pharmacology , Quinones , Skin/drug effects , Animals , Dose-Response Relationship, Drug , Drug Interactions , Female , Mice , Mice, Inbred CBA , Sensitivity and Specificity , Skin/immunologyABSTRACT
BACKGROUND: The murine local lymph node assay (LLNA) has recently been endorsed as a validated alternative to guinea pig methods for the identification of skin sensitization hazard. Nevertheless, there has been some debate regarding the utility of this method for the detection of metal contact allergens. OBJECTIVE: In these investigations, we have used the LLNA to determine the skin sensitization potential of 13 metal salts, 8 of which were considered to possess a significant ability to sensitize man, whereas the remaining 5 were judged to lack such potential. RESULTS: The predictions from the LLNA were correct for 7 of the 8 (88%) sensitizing metals and for 4 of the 5 (80%) nonsensitizers when considered against the experience of these metals as human skin sensitizers. Thus, the overall predictive accuracy of the LLNA in relation to metals was 11/13 (85%), which is very similar to the accuracy of approximately 88% in relation to a much larger number of low-molecular-weight organic chemicals, as reported previously. CONCLUSION: These data provide support for the potential utility of the LLNA in hazard identification of metal contact allergens.
Subject(s)
Allergens/analysis , Dermatitis, Allergic Contact/diagnosis , Lymph Nodes/chemistry , Metals/analysis , Allergens/immunology , Animals , Culture Techniques , Dermatitis, Allergic Contact/immunology , Dermatitis, Allergic Contact/prevention & control , Female , Humans , Lymph Nodes/immunology , Male , Metals/immunology , Mice , Mice, Inbred CBA , Patch Tests , Predictive Value of Tests , Sensitivity and SpecificityABSTRACT
Conjugated linoleic acid (CLA) is reported as having several beneficial effects including anticarcinogenic, cholesterol-lowering and anti-atherogenic properties; however, CLA has also been reported as a putative peroxisome proliferator in mice. In this study the ability of CLA to cause peroxisome proliferation in the rat, as measured by accepted enzyme markers was investigated. Male Wistar rats were fed a semi-purified diet containing 0.0, 1.5 or 5.0 energy % CLA for 4 weeks. A positive control group were given 250 mg clofibrate/kg by gavage for 4 days. Hepatic cyanide-insensitive palmitoyl coenzyme A (PCoA) oxidase and carnitine acetyl transferase (CAT) activities and total cytochrome P450 (CYP) levels were measured. CLA had no effect on body weight or liver/body weight ratios, but clofibrate significantly increased mean liver/body weight ratio by 41.6%. Clofibrate-treated rats showed typical changes with increases in hepatic PCoA oxidase and CAT activity (5.8-fold and 22.8-fold) and in total CYP (1.66-fold) compared with control. There were no differences between the control group and the groups fed CLA for either the peroxisomal enzymes or total CYP. These results suggest that CLA does not act in the rat as a classical peroxisome proliferator and that there may be a species difference in the effects on rat and mice.
Subject(s)
Linoleic Acids/toxicity , Peroxisome Proliferators/toxicity , Animals , Body Weight/drug effects , Carnitine O-Acetyltransferase/metabolism , Clofibrate/toxicity , Cytochrome P-450 Enzyme System/metabolism , Drinking/drug effects , Eating/drug effects , Isomerism , Linoleic Acids/chemistry , Liver/anatomy & histology , Liver/drug effects , Liver/enzymology , Male , Organ Size/drug effects , Oxidoreductases/metabolism , Peroxisome Proliferators/chemistry , Rats , Rats, WistarABSTRACT
The murine local lymph node assay (LLNA) is a method for the prospective identification of skin sensitizing chemicals. Proliferative responses induced in lymph nodes draining the site of topical application of the test chemical are measured and those chemicals that induce a stimulation index of three or more compared with concurrent vehicle-treated controls are considered to have the potential to cause skin sensitization. Dose-response data from the LLNA may be used to derive an estimate of relative skin sensitizing potency, based upon derivation of the concentration of chemical required to cause a stimulation index of 3 (EC3 value) as calculated by linear interpolation. The purpose of the present investigations was to examine the stability of LLNA responses and the consistency of derived EC3 values induced by the contact allergen paraphenylenediamine (PPD). Analyses were conducted once a month over a 4-month period in each of two independent laboratories. In all assays, and in both laboratories, PPD elicited a positive response. Although some minor differences in responses between and within laboratories were observed, the derived EC3 values were generally very consistent. In Laboratory 1, EC3 values varied between 0.06 and 0.09% PPD, whereas in Laboratory 2 the range was 0.09-0.20%. These EC3 values are consistent with clinical experience of this material insofar as it is a common and relatively potent cause of allergic contact dermatitis in humans. Taken together, these data confirm the stability of LLNA responses both with time and between laboratories and provide additional support for the use of derived EC3 values in the assessment of relative skin sensitizing potency.
Subject(s)
Allergens/toxicity , Lymph Nodes/drug effects , Lymphocyte Activation/drug effects , Phenylenediamines/toxicity , Animals , Cell Separation , Dermatitis, Contact/etiology , Disease Models, Animal , Dose-Response Relationship, Drug , Female , Laboratories/standards , Lymph Nodes/metabolism , Lymph Nodes/pathology , Mice , Mice, Inbred CBA , Predictive Value of Tests , Time Factors , Toxicity TestsABSTRACT
Effective risk assessment and management of allergic contact dermatitis require three key factors: adequate hazard identification, measurement of the relative potency of identified hazards and an understanding of the nature, extent and duration of exposure. Suitable methods for hazard identification, such as the murine local lymph node assay (LLNA) and the guinea-pig maximization test, are well established and conditions of human exposure normally can be well anticipated. Thus, the need is for a robust and quantitative method for the estimation of relative skin sensitizing potency. One possible approach is via the analysis of LLNA dose-response data. In the LLNA, contact allergens are defined currently as those chemicals that cause a threefold or greater increase in lymph node cell proliferative activity compared with concurrent vehicle-treated controls. It is possible to estimate the concentration of a sensitizer required to generate a threefold stimulation of proliferation in draining lymph nodes; such a concentration is known as the EC3 value. Using a variety of statistical approaches to derive EC3 values from LLNA dose-response data for 10 chemicals, it has been demonstrated that simple linear interpolation between the values either side of the threefold stimulation index provides a robust assessment of the EC3 value without the need for recourse to more sophisticated statistical techniques. Provided that the appropriate concentrations of test chemical have been selected, EC3 values obtained in this way are reproducible both within and between laboratories and form the basis for examination of the utility of this approach for the estimation of relative skin sensitizing potency.
Subject(s)
Allergens/toxicity , Data Interpretation, Statistical , Lymph Nodes/drug effects , Lymphocyte Activation/drug effects , Models, Statistical , Animals , Dose-Response Relationship, Drug , Linear Models , Lymph Nodes/metabolism , Lymph Nodes/pathology , Mice , Mice, Inbred CBA , Predictive Value of Tests , Toxicity TestsABSTRACT
Phytosterols are natural constituents of the human diet, and as part of an extensive programme of safety evaluation studies investigating their use as a novel food ingredient, the possible oestrogenic effects of phytosterols have been investigated using a combination of in vitro and in vivo assays. Competitive binding with the immature rat uterine oestrogen receptor (ER) has been used to measure the ability of phytosterols to bind to ERs while the transcriptional activation of oestrogen-responsive genes has been examined in an oestrogen-inducible yeast screen. Phytosterols did not display any activity in these in vitro assays. Uterotrophic assays have been conducted to investigate the potential for phytosterols to elicit an oestrogenic response when administered orally to immature female rats (n = 10) at doses of 0, 5, 50 or 500 mg/kg/day for 3 consecutive days. Phytosterols (a well characterized mixture of beta-sitosterol, campesterol and stigmasterol) and phytosterol esters (the previous phytosterol mixture esterified with fatty acids from sunflower oil) did not exhibit oestrogenic activity in the immature female rat using uterine wet weight as the endpoint. Beta-oestradiol (0.4 mg/kg/day) consistently produced a significant increase in uterus weights. Coumestrol (a known phytoestrogen) was also tested as a weak positive control and produced a dose response at doses of 20, 40 and 80 mg/kg/day in the uterotrophic assay. In conclusion, we have shown that phytosterols do not bind to the ER and do not stimulate transcriptional activity of the human ER in a recombinant yeast strain. In addition, there was no indication of oestrogenicity from the uterotrophic assay when the material was administered by oral gavage to immature female rats.
Subject(s)
Estrogens, Non-Steroidal/pharmacology , Phytosterols/pharmacology , Receptors, Estrogen/drug effects , Uterus/drug effects , Administration, Oral , Animals , Binding, Competitive , Cholesterol/administration & dosage , Cholesterol/analogs & derivatives , Cholesterol/pharmacology , Coumestrol/pharmacology , Dose-Response Relationship, Drug , Esters , Estradiol/pharmacology , Estrogens, Non-Steroidal/administration & dosage , Estrogens, Non-Steroidal/metabolism , Female , Organ Size/drug effects , Phytosterols/administration & dosage , Phytosterols/metabolism , Rats , Rats, Wistar , Receptors, Estrogen/metabolism , Saccharomyces cerevisiae/drug effects , Sitosterols/administration & dosage , Sitosterols/pharmacology , Stigmasterol/administration & dosage , Stigmasterol/pharmacology , Uterus/anatomy & histologyABSTRACT
For more than 15 years, the murine local lymph node assay (LLNA) has undergone development, evaluation and validation as an alternative approach to the predictive identification of skin sensitizing chemicals. The criteria by which sensitizing chemicals are distinguished from those without significant skin sensitising hazard were developed empirically and were based on experience rather than a mathematical formula or statistical method. The current practice is to classify, as skin sensitizers, those chemicals which at one or more test concentrations stimulate a threefold or greater increase in the proliferative activity in draining lymph node cells. Despite the apparent confirmation of the utility of this approach from the extensive data available, there has not previously been any attempt to substantiate the accuracy of this criterion. In this present investigations, data from 134 chemicals tested in the LLNA and in the guinea pig and/or for which there exists clear evidence relating to human skin sensitization potential, have been subjected to a rigorous statistical evaluation using Receiver Operating Characteristic (ROC) curves. Whether the analysis is based on a comparison with guinea pig or human data, the results indicate that the empirically derived threefold threshold is an acceptable practical value for hazard identification.